| Literature DB >> 34088653 |
Susana P Fernández Sánchez1, Fermín Rodríguez Muñoz2, Ana Laiz3, Ivan Castellví3, Berta Magallares1, Héctor Corominas4.
Abstract
OBJECTIVE: The COVID-19 pandemic has brought major changes to the model of patient care in Rheumatology. Our aim was to compare the change in the care delivered in a rheumatology nursing consultation before and during the pandemic.Entities:
Keywords: Actividad; Activity; COVID-19; Enfermería reumatología; Impact; Impacto; Outbreak; Pandemia; Rheumatology nursing
Mesh:
Year: 2021 PMID: 34088653 PMCID: PMC8169321 DOI: 10.1016/j.reumae.2021.02.001
Source DB: PubMed Journal: Reumatol Clin (Engl Ed) ISSN: 2173-5743
Descriptive analysis of the sample which regularly attends monographic rheumatology nursing consultation before and that observed ruing the first wave of the COVID-19 pandemic.
| Before COVID-19 | During COVID-19 | ||
|---|---|---|---|
| Variables | Mean (SD) | Mean (SD) | |
| Age (years) | 61 (±17) | 57 (±18) | .053 |
SD: Standard Deviation.
Fisher's test.
Chi-squared (likelihood ratio).
Change observed in the frequency of interventions carried out by rheumatology nursing before and during the pandemic.
| Before 254, n (%) | During 251, n (%) | ||
|---|---|---|---|
| | |||
| Face-to-face | 61 (35) | 3 (42.9) | .676 |
| Non Face-to-face | 10 (12.7) | 15 (6.1) | .073 |
| | |||
| Face-to-face | 18 (10.3) | 1 (14,3) | .750 |
| Non Face-to-face | 2 (2.5) | 0 (0) | .017 |
| | |||
| Face-to-face | 49 (28.2) | 0 (0) | .049 |
| Non Face-to-face | 2 (2.5) | 93 (38,1) | <.001 |
| | |||
| Face-to-face | 24 (13,8) | 0 (0) | .154 |
| Non Face-to-face | 2 (2,5) | 34 (14) | .001 |
| | |||
| Face-to-face | 38 (21,8) | 0 (0) | .066 |
| Non Face-to-face | 0 (0) | 6 (2,5) | .065 |
| | |||
| Face-to-face | 40 (23) | 0 (0) | .059 |
| Non Face-to-face | 2 (2,5) | 0 (0) | .017 |
| | |||
| Face-to-face | 4 (2,3) | 4 (57,1) | <.001 |
| Non Face-to-face | 0 (0) | 1 (.4) | .453 |
| | |||
| Face-to-face | 9 (5.2) | 1 (14.3) | .379 |
| Non Face-to-face | 22 (27.8) | 96 (39.5) | .058 |
| Face-to-face | |||
| Outbreak | 15 (5.9) | 4 (1.6) | <.001 |
| Side effect | 3 (1.2) | 0 (0) | |
| Activate treatment | 1 (.4) | 1 (.4) | |
| Doubts | 5 (2) | 0 (0) | |
| Administrative | 4 (1.6) | 0 (0) | |
| | |||
| Outbreak | 11 (4.3) | 8 (3.2) | <.001 |
| Side effect | 5 (2) | 2 (.8) | |
| Activate treatment | 3 (1.2) | 1 (.4) | |
| Doubts | 35 (13.8) | 78 (31.1) | |
| Administrative | 14 (5.5) | 3 (1.2) | |
Chi-squared (likelihood ratio).